The Emerging Opportunities In 65+

This past week brought news of potential entrants in the senior behavioral health market space. On the pharmaceutical front, a new drug, lecanemab, was shown to slow cognitive decline in consumers with early Alzheimer’s disease. In the study, lecanemab reduced accumulation of the amyloid plaque proteins that cause the onset and progression of the disease (see ‘Game changer’: Alzheimer’s Drug Lecanemab Slows Progression Of Disease In Global Study and Lecanemab: FDA Set Accelerated Approval Decision For January 2023). And a few months ago, the medication Rexulti was shown to reduce agitation in consumers with Alzheimer's disease (see . . .